18+ Adults only. We do not sell to anyone under 18. Research compounds are supplied for research use only.
GLP-1, insulin and metabolic health, with fresh produce at an outdoor market

GLP-1, insulin and metabolic health, explained simply

GLP-1 has gone from a term only endocrinologists used to something people mention at braais. But most explanations stop at “it makes you less hungry”, which misses most of what it does and why it matters for long-term health. This is the plain version: what GLP-1 and insulin actually do, what goes wrong in insulin resistance, and why the newest compounds add two more hormones to the mix.

GLP-1, insulin and metabolic health in 60 seconds

  • Insulin moves sugar out of the blood and into your cells, and tells the body to store energy.
  • Insulin resistance is when cells stop responding well, so the body has to make more and more insulin to do the same job.
  • GLP-1 is a gut hormone that helps release insulin only when blood sugar is high, slows the stomach and tells the brain you are full.
  • Tirzepatide adds GIP, a second gut hormone, and retatrutide adds glucagon, which pushes energy use up.

Insulin: the storage hormone

Every time you eat carbohydrate, blood sugar rises and the pancreas releases insulin. Insulin opens the door for that sugar to move into muscle, liver and fat cells, and it switches the body into storage mode: build glycogen, store fat, stop releasing it. When things work well, sugar comes back down within a couple of hours and insulin falls with it.

Insulin resistance: when the signal stops getting through

With excess body fat, particularly fat around the organs, inactivity, poor sleep and time, cells can become less responsive to insulin. The pancreas compensates by producing more. For years, blood sugar can look normal while insulin quietly climbs, which keeps the body in storage mode and makes fat harder to lose. Eventually the pancreas cannot keep up, blood sugar starts to rise, and that is the road to type 2 diabetes.

The markers that usually travel together are a large waist, raised fasting glucose or HbA1c, high triglycerides, low HDL cholesterol and raised blood pressure. Several of them together is what doctors call metabolic syndrome.

What GLP-1 does

Spider diagram of what GLP-1 does: more insulin and less glucagon from the pancreas, slower stomach emptying, fullness signals in the brain and fewer heart events

GLP-1 is released by cells in your gut after you eat, and it acts in several places at once:

  • In the pancreas, it boosts insulin release, but only when blood sugar is raised. That is why GLP-1 on its own rarely drops blood sugar too low.
  • Also in the pancreas, it lowers glucagon, the hormone that tells the liver to release more sugar.
  • In the stomach, it slows emptying, so food arrives more gradually and you stay full for longer.
  • In the brain, it acts on the appetite centres. This is the “food noise” people talk about quietening.
  • In the heart, a large semaglutide trial in people with overweight and existing heart disease found about 20% fewer major heart events, the first time a weight-loss medicine showed that.

Your own GLP-1 lasts only about two minutes in the blood. The compounds in this class are engineered to last about a week, which is the whole difference between a mealtime signal and a strong, steady effect. Our piece on peptide half-lives explains how.

Why GIP and glucagon were added

GIP is the other gut hormone involved in the insulin response after a meal. Combining it with GLP-1 in one molecule, as tirzepatide does, produced more weight loss in trials than semaglutide alone, although exactly how GIP contributes is still debated.

Glucagon is the surprising addition, because it normally raises blood sugar. Retatrutide adds it in a balanced way, so the GLP-1 effect keeps blood sugar in check while glucagon pushes up energy expenditure and helps clear fat from the liver. In its trials, retatrutide produced the largest average weight loss of the three, along with large reductions in liver fat.

Three gut hormones, three jobs

  1. GLP-1: helps release insulin only when blood sugar is high, slows the stomach and tells the brain you are full
  2. GIP (added in tirzepatide): a second gut hormone
  3. Glucagon (added in retatrutide): pushes energy use up

Where peptides fit, and where they do not

These compounds are powerful tools for the appetite and blood sugar side of metabolic health. They do not replace the basics that improve insulin sensitivity directly: regular movement, resistance training to build and keep muscle, enough sleep and enough protein. Muscle is the biggest place the body stores sugar, which is why keeping it during weight loss matters so much. We cover that in retatrutide and tesamorelin.

Frequently asked questions

What does GLP-1 do in the body?

GLP-1 is a gut hormone released after eating. It increases insulin release when blood sugar is high, lowers glucagon, slows stomach emptying and signals fullness to the brain.

What is insulin resistance?

It is when cells respond less well to insulin, so the pancreas has to make more of it to keep blood sugar normal. Over time this keeps the body in fat-storage mode and can lead to type 2 diabetes.

Why does tirzepatide include GIP?

GIP is a second gut hormone involved in the insulin response to food. Combining it with GLP-1 in one molecule produced more weight loss in trials than GLP-1 alone.

Why does retatrutide include glucagon if glucagon raises blood sugar?

In retatrutide, the GLP-1 and GIP actions keep blood sugar in check, while the glucagon action increases energy expenditure and helps clear fat from the liver.

Sources

  • Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews, 2007.
  • Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine, 2023.
  • Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
  • Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 2023.

This article is for educational purposes only and is not medical advice. Retatrutide is an investigational compound and the products we stock are sold for research use.

Related reading: slimming injections in South Africa.

For how the three main compounds compare, read retatrutide vs tirzepatide vs semaglutide. For the compounds that work on energy use rather than appetite, see fat-loss peptides that are not GLP-1s.